GNI Group (2160) Price & Analysis

Compare

2 Followers

2160 Stock Chart & Stats

Day’s Range― - ―

52-Week Range¥1,469.00 - ¥4,410.00

Previous CloseN/A

Volume492.20K

Average Volume (3M)2.19M

Market Cap

¥156.92B

Enterprise Value¥55.62B

Total Cash (Recent Filing)¥9.93B

Total Debt (Recent Filing)¥6.62B

Price to Earnings (P/E)108.8

Beta1.52

Next Earnings

Aug 14, 2025

EPS Estimate

130.45

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-10.57

Shares Outstanding50,538,445

10 Day Avg. Volume1,661,320

30 Day Avg. Volume2,191,026

Financial Highlights & Ratios

PEG Ratio0.05

Price to Book (P/B)3.15

Price to Sales (P/S)0.00

P/FCF Ratio-42.76

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

¥3,827.33

Price Target Upside23.26% Upside

Rating ConsensusHold

Number of Analyst Covering1

GNI Group News

PremiumCompany Announcements

GNI Group’s Cullgen Nears Nasdaq Listing After Shareholder Approval

26d ago

PremiumCompany Announcements

GNI Group’s Gyre Therapeutics Begins Phase 1 Trial for PAH Drug in China

1M ago

PremiumCompany Announcements

GNI Group’s Gyre Pharmaceuticals Launches Etorel for Pulmonary Fibrosis

1M ago

PremiumCompany Announcements

GNI Group’s Subsidiary Gyre Therapeutics Completes Successful Public Offering

1M ago

PremiumCompany Announcements

GNI Group’s Liver Fibrosis Drug Achieves Key Trial Success in China

2M ago

PremiumCompany Announcements

Gyre Therapeutics Launches $20 Million Public Stock Offering

2M ago

PremiumCompany Announcements

GNI Group Reports Decline in Q1 FY2025 Financial Results

2M ago

PremiumCompany Announcements

GNI Group Confirms NDA Timeline for Hydronidone

2M ago

See All JP:2160 News

See All News >

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

0.45%

Mutual Funds

― Other Institutional Investors

97.15% Public Companies and

Individual Investors

Detailed Ownership Overview >

2160 FAQ

What was GNI Group ’s price range in the past 12 months?

GNI Group lowest stock price was ¥1469.00 and its highest was ¥4410.00 in the past 12 months.

What is GNI Group ’s market cap?

GNI Group ’s market cap is ¥156.92B.

When is GNI Group ’s upcoming earnings report date?

GNI Group ’s upcoming earnings report date is Aug 14, 2025 which is in 32 days.

How were GNI Group ’s earnings last quarter?

GNI Group released its earnings results on May 15, 2025. The company reported -¥10.57 earnings per share for the quarter, missing the consensus estimate of ¥27.86 by -¥38.43.

Is GNI Group overvalued?

According to Wall Street analysts GNI Group ’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does GNI Group pay dividends?

GNI Group does not currently pay dividends.

What is GNI Group ’s EPS estimate?

GNI Group ’s EPS estimate is 130.45.

How many shares outstanding does GNI Group have?

GNI Group has 50,538,445 shares outstanding.

What happened to GNI Group ’s price movement after its last earnings report?

GNI Group reported an EPS of -¥10.57 in its last earnings report, missing expectations of ¥27.86. Following the earnings report the stock price went down -3.231%.

Which hedge fund is a major shareholder of GNI Group ?

Currently, no hedge funds are holding shares in JP:2160

Company Description

GNI Group

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs and traditional Chinese medicines in Japan and internationally. It provides Etuary for the treatment of idiopathic pulmonary fibrosis. The company is also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial phase II and pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, it is involved in developing F351, which is in Phase II clinical trial for the treatment of liver fibrosis; and F573 that is in pre-clinical phase for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.

2160 Stock 12 Month Forecast

Average Price Target

¥3,827.33

▲(23.26%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2202":"¥2,202","4061":"¥4,061","2666.75":"¥2,666.8","3131.5":"¥3,131.5","3596.25":"¥3,596.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":3827.3306910486,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">¥3.83K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3827.3306910486,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">¥3.83K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3827.3306910486,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">¥3.83K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2202,2666.75,3131.5,3596.25,4061],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2024","6":"Jun<br/>2024","9":"Sep<br/>2024","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4060,4042.102360849892,4024.2047216997844,4006.307082549677,3988.409443399569,3970.5118042494614,3952.6141650993536,3934.7165259492463,3916.8188867991385,3898.9212476490306,3881.023608498923,3863.1259693488155,3845.2283301987077,{"y":3827.3306910486,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4060,4042.102360849892,4024.2047216997844,4006.307082549677,3988.409443399569,3970.5118042494614,3952.6141650993536,3934.7165259492463,3916.8188867991385,3898.9212476490306,3881.023608498923,3863.1259693488155,3845.2283301987077,{"y":3827.3306910486,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4060,4042.102360849892,4024.2047216997844,4006.307082549677,3988.409443399569,3970.5118042494614,3952.6141650993536,3934.7165259492463,3916.8188867991385,3898.9212476490306,3881.023608498923,3863.1259693488155,3845.2283301987077,{"y":3827.3306910486,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3120,"date":1701388800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2830,"date":1704067200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2619,"date":1706745600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3285,"date":1709251200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":3065,"date":1711929600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2432,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2203,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2340,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2215,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2247,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2247,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2390,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4060,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >